Syros Pharmaceuticals (NASDAQ:SYRS) had its price objective lowered by Piper Jaffray Companies from $24.00 to $18.00 in a research report released on Thursday, October 17th, The Fly reports.
Other equities research analysts also recently issued reports about the company. Zacks Investment Research upgraded Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, September 28th. ValuEngine downgraded Syros Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, October 7th. Roth Capital initiated coverage on Syros Pharmaceuticals in a research report on Friday, July 12th. They issued a buy rating and a $17.00 target price on the stock. Finally, BidaskClub downgraded Syros Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, October 4th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $13.46.
NASDAQ SYRS traded down $0.03 during trading on Thursday, reaching $5.21. The company’s stock had a trading volume of 185,300 shares, compared to its average volume of 195,726. The firm has a fifty day moving average of $7.79 and a 200 day moving average of $8.00. Syros Pharmaceuticals has a one year low of $5.11 and a one year high of $11.93. The stock has a market capitalization of $223.65 million, a PE ratio of -2.73 and a beta of 1.49. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.11 and a quick ratio of 8.11.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its stake in shares of Syros Pharmaceuticals by 863.4% during the third quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock valued at $28,000 after buying an additional 2,409 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Syros Pharmaceuticals by 11,319.2% during the second quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock valued at $27,000 after buying an additional 2,943 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Syros Pharmaceuticals by 1.7% during the second quarter. JPMorgan Chase & Co. now owns 407,843 shares of the company’s stock valued at $3,242,000 after buying an additional 6,771 shares during the last quarter. A.R.T. Advisors LLC bought a new position in shares of Syros Pharmaceuticals during the second quarter valued at approximately $119,000. Finally, Susquehanna International Group LLP bought a new position in shares of Syros Pharmaceuticals during the second quarter valued at approximately $133,000. 85.96% of the stock is currently owned by hedge funds and other institutional investors.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More: Intrinsic Value and Stock Selection
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.